The "RIPK1 inhibitor - Pipeline Insights, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
The publisher's, "RIPK1 inhibitors - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"RIPK1 inhibitors - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RIPK1 inhibitors pipeline landscape is provided which includes the disease overview and RIPK1 inhibitors treatment guidelines.
The assessment part of the report embraces, in depth RIPK1 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RIPK1 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence RIPK1 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve RIPK1 inhibitors.
This segment of the RIPK1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RIPK1 inhibitors Emerging DrugsSAR443122: Sanofi
SAR443122: SanofiAR443122 (DNL758) is a small molecule inhibitor of a protein known as RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which is involved in the tumor necrosis factor (TNF) receptor pathway that is implicated in inflammation, immunity, and cell death. RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.
Sanofi has successfully completed the Phase I study with peripherally-restricted RIPK1 inhibitor DNL758(c) to treat SARS-CoV-2 viral infection and conducting Phase II clinical trial to treat Cutaneous Lupus Erythematosus. Furthermore, Sanofi plans to initiate a Phase II trial of SAR443122 in patients with ulcerative colitis.
GFH312: GenFleet Therapeutics
GFH312: GenFleet Therapeutics's GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF- downstream. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage.
Preclinical data of GFH312 have demonstrated its effects in suppressing inflammation (peripheral and neuronal), reducing pathological as well as behavioral deficits, and improving survival in animal models with acute systemic inflammation resulting from multiple tissue injury. GFH312 effectively inhibit the activity of RIPK1, and the Phase I trial will explore its safe dose range and tolerability in healthy subjects providing basis for further clinical development.
R552: Rigel Pharmaceuticals
R552: Rigel Pharmaceuticals552, the drug is supposed to block an enzyme that plays a role in a wide range of cellular processes, including inflammation and cell death. Eli Lilly and Rigel Pharmaceuticals have collaborated to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases. Rigel's lead RIPK1 inhibitor, R552, has completed Phase I clinical trials and the planning to begin Phase II clinical trials is underway as part of the collaboration.
